About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker ACAD · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 5, 2026ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
NCT07284667 · Major Depressive Disorder (MDD), Depressive Disorder, Treat…
ACP-211, Placebo
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2Recruiting153Aug 2027Registry ↗
Nov 5, 2026ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673 · Alzheimer's Disease Psychosis
ACP-204, Placebo
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2/3Recruiting1,074Jan 2028Registry ↗
Nov 4, 2026Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
NCT07095465 · Lewy Body Dementia Psychosis
ACP-204
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Recruiting126Feb 2029Registry ↗
Nov 4, 2026Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
NCT07029581 · Lewy Body Dementia Psychosis
ACP-204, Placebo
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2Recruiting180Feb 2028Registry ↗
Nov 4, 2026ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
NCT06194799 · Alzheimer's Disease Psychosis
ACP-204
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Enrolling by invitation752Apr 2029Registry ↗
Oct 15, 2026Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
NCT06173531 · Hyperphagia in Prader-Willi Syndrome
Carbetocin, Placebo
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Completed175Aug 19, 2025Registry ↗
Aug 17, 2026OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
NCT06420297 · Hyperphagia in Prader-Willi Syndrome
Carbetocin
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Terminated168Dec 19, 2025Registry ↗
Dec 3, 2025Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
NCT05555615 · Irritability Associated With Autism Spectrum Disorder
Pimavanserin
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2/3Terminated209Feb 14, 2025Registry ↗
Aug 24, 2025Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
NCT05523895 · Irritability Associated With Autism Spectrum Disorder
Pimavanserin, Placebo
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2/3Completed237Sep 27, 2024Registry ↗
Aug 24, 2025Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
NCT03121586 · Schizophrenia
Pimavanserin
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Terminated995Apr 30, 2024Registry ↗
Aug 22, 2025Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophre…
NCT04531982 · Schizophrenia
Pimavanserin, Placebo
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Completed454Jan 25, 2024Registry ↗
Jan 20, 2025ACP-104 in Acutely Psychotic Subjects With Schizophrenia
NCT00490516 · Schizophrenia
ACP-104, ACP-104
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2Completed247Feb 2008Registry ↗
Jan 14, 2025Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disea…
NCT04292223 · Parkinson Disease Psychosis
Pimavanserin
ACAD
ACADIA Pharmaceuticals Inc.
Phase 4Completed29Apr 26, 2022Registry ↗
Jan 9, 2025Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of…
NCT05008835 · Osteoarthritis Pain
ACP-044 Dose A, ACP-044 Dose B
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2Terminated61Oct 6, 2022Registry ↗
Dec 31, 2024A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms…
NCT03575052 · Neuropsychiatric Symptoms Related to Neurodegenerative Dise…
Pimavanserin, Placebo
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Completed784May 6, 2022Registry ↗
Dec 20, 2024Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurode…
NCT03623321 · Neuropsychiatric Symptoms Related to Neurodegenerative Dise…
Pimavanserin
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Completed595May 5, 2023Registry ↗
Sep 27, 2024Open-Label Extension Study of Trofinetide for Rett Syndrome
NCT04776746 · Rett Syndrome
trofinetide
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Terminated77Jun 30, 2023Registry ↗
Sep 24, 2024An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Ret…
NCT04988867 · Rett Syndrome
Trofinetide
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2/3Terminated15May 31, 2023Registry ↗
Apr 11, 2024Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome
NCT04279314 · Rett Syndrome
Trofinetide
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Completed154Aug 19, 2022Registry ↗
Apr 8, 2024Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
NCT04181723 · Rett Syndrome
Trofinetide, Placebo
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Completed187Oct 28, 2021Registry ↗
May 3, 2023Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following…
NCT04855240 · Acute Postoperative Pain, Bunionectomy
ACP-044 Dose A, ACP-044 Dose B
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2Completed239Feb 11, 2022Registry ↗
Apr 5, 2022Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response…
NCT04000009 · Adjunctive Treatment of Major Depressive Disorder
Pimavanserin
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Terminated235Feb 22, 2021Registry ↗
Nov 17, 2021Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antid…
NCT03968159 · Adjunctive Treatment of Major Depressive Disorder
Pimavanserin, Placebo
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Completed298Apr 30, 2020Registry ↗
Oct 14, 2021Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychi…
NCT04164758 · Parkinson's Disease
Pimavanserin, Placebo
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2Terminated11Sep 25, 2020Registry ↗
Aug 6, 2021The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
NCT03152292 · Parkinson Disease Psychosis
Real-world, non-interventional
ACAD
ACADIA Pharmaceuticals Inc.
—Terminated764Mar 8, 2021Registry ↗
Jun 21, 2021Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
NCT03325556 · Dementia-related Psychosis
Placebo, Pimavanserin 34 mg
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Completed392Jul 31, 2019Registry ↗
Dec 22, 2020Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophre…
NCT02970305 · Schizophrenia
Pimavanserin, Placebo
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2Completed403Oct 16, 2019Registry ↗
Nov 23, 2020An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
NCT01518309 · Parkinson's Disease Psychosis
pimavanserin tartrate (ACP-103)
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2Completed39May 2, 2013Registry ↗
Aug 31, 2020Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
NCT03482882 · Treatment of Depression in Adults With Parkinson's Disease…
Pimavanserin
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2Completed47Jul 9, 2019Registry ↗
Jun 17, 2020Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
NCT02970292 · Schizophrenia
Pimavanserin, Placebo
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Completed396May 28, 2019Registry ↗
Apr 9, 2020A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's…
NCT03118947 · Agitation and Aggression in Alzheimer's Disease
Pimavanserin
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2Completed79Feb 25, 2019Registry ↗
Nov 14, 2019Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (…
NCT03018340 · Adjunctive Treatment of Major Depressive Disorder
Pimavanserin, Placebo
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2Completed207Sep 2018Registry ↗
Jun 24, 2019A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disea…
NCT00550238 · Parkinson's Disease Psychosis
Pimavanserin tartrate (ACP-103)
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Completed459May 30, 2018Registry ↗
Mar 28, 2019Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggress…
NCT02992132 · Agitation and Aggression in Alzheimer's Disease
Pimavanserin 34 mg, Pimavanserin 20 mg
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2Terminated111Jan 25, 2018Registry ↗
Oct 25, 2017A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
NCT02035553 · Alzheimer's Disease Psychosis
Pimavanserin tartrate, Placebo
ACAD
ACADIA Pharmaceuticals Inc.
Phase 2Completed181Sep 28, 2016Registry ↗
May 19, 2017A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psych…
NCT00658567 · Parkinson's Disease Psychosis
Pimavanserin tartrate (ACP-103), Pimavanserin tartrate (ACP…
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Completed123Dec 2009Registry ↗
May 17, 2017A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease P…
NCT00477672 · Parkinson's Disease Psychosis
Pimavanserin tartrate (ACP-103), Pimavanserin tartrate (ACP…
ACAD
ACADIA Pharmaceuticals Inc.
Phase 3Completed298Jun 2009Registry ↗
Apr 18, 2017Expanded Access of Pimavanserin for Patients With PD Psychosis
NCT02762591 · Parkinson's Disease Psychosis
Pimavanserin tartrate
ACAD
ACADIA Pharmaceuticals Inc.
—Approved for marketing——Registry ↗

38 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:31 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances